

# RECEIVED

MAR 3 1 2003

rney Docket No : LIBC P-020

Attorney Docket No.: UBC.P-020
PATENT APPLICATION
March 21, 2003

TECH CENTER 1600/2965

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Gleave, et al.

Serial No : Confirmation :

09/913,325 8469

Filed

08/10/2001

Title

TRPM-2 Antisense Therapy

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner Patents and Trademarks Washington, DC 20231

Sir:

Applicants request that the references listed on Substitute Form PTO-1449, which is enclosed, be made of record in the Patent Office file relating to the above-captioned application. Copies of the references are provided herewith. No fee is believed to be due with this paper as we have not received an action on the merits. The Commissioner is authorized to charge any fees due to Deposit Account Number 15-0610.

Respectfully submitted,
OPPEDAHL & LARSON LLP

Marina T. Larson, PhD , Reg. No.  $32,\!038$ 

Marina & darook

P.O. Box 5068

Dillon, CO 80435-5068

970-468-6600

#### **CERTIFICATE OF MAILING UNDER 37 CFR §1.8(a)**

I hereby certify that this paper and the attachments named herein are being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on 3/24/52

3 24 03
Date of Signature

Nichole P. Larson

#9

Substitute for form 1449

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

RECEIVED

MAR 31 2003

TECH CENTER 1600/2900

Application No.:

09/913,325

Applicant: Filing Date: Gleave, et al. 08/10/2001

Conf. No.:

8469

Title: TRPM-2 Antisense Therapy

Attorney Docket No.:

UBC.P-020

Page 1 of 2

## U.S. PATENT DOCUMENTS

Examiners Initials	U S Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
	5,789,389	Tarasewicz et al.	08/04/1998
	6,335,194 B1	Bennett et al.	01/01/2002

### FOREIGN PATENT DOCUMENTS

Examiners Initials	Patent No.	Name of Persons or applicant	Date of Publication of Cited Document
	WO 01/46455 A2	Yale University	06/28/2001

### OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

	O MADE THE THE THE POPULATION OF THE POPULATION
Examiner Initials	
	Nör et al.; Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth; Cancer Research; Vol. 61; March 1, 2001; 2183-2188.
	Kirby et al.; Bartonella-Associated Endothelial Proliferation Depends on Inhibition of Apoptosis; PNAS; Vol. 99, No. 7; April 2, 2002; 4656-4661.
	Cox et al.; Angiogenesis and Non-Small Cell Lung Cancer; Lung Cancer; Vol. 27, 2000; 81-100.
	Tran et al.; A Role for Survivin in Chemoresistance of Endothelial Cells Mediated by VEGF; PNAS; Vol. 99, No. 7; April 2, 2002; 4349-4354.
	Nör et al.; Engineering and Characterization of Functional Human Microvessels in Immunodeficient Mice; Laboratory Investigation; Vol. 81, No.4; April 2001; 453-463.
	Boral et al.; Clinical Evaluation of Biologically Targeted Drugs: Obstacles and Opportunities; Cancer Chemother Pharmacol; Vol. 42; 1998; S3-S21.

MAR 27 2003 E

RECEIVED

MAR: 31 2003

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
TECH CENTER 1600/2900

Application No.:

09/913,325

Applicant: Filing Date:

Gleave, et al. 08/10/2001

Conf. No.:

8469

Title: TRPM-2 Antisense Therapy

Attorney Docket No.:

UBC.P-020

Page 2 of 2

Zwain et al.; Clusterin Protects Granulosa Cells from Apoptotic Cell Death During Follicular Atresia; Experimental Cell Research; Vol. 257; 2000; 101-110.
Lee et al.; In Vitro Models of Prostate Apoptosis: Clusterin as an Antiapopotic Mediator; The Prostate Supplement; Vol. 9; 2000; 21-24.
Genta Incorporated; New Data Reaffirm Genta's Molecular Target as Critical Factor for Enhancing Anticancer Treatment; <a href="www.genta.com">www.genta.com</a> : 2001.

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

	·
Examiner Signature	Date Considered